Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Michelle Lewis is active.

Publication


Featured researches published by Michelle Lewis.


Journal of Biomolecular Screening | 2011

A Biochemical Screen for Identification of Small-Molecule Regulators of the Wnt Pathway Using Xenopus Egg Extracts

Curtis A. Thorne; Bonnie LaFleur; Michelle Lewis; Alison J. Hanson; Kristin K. Jernigan; David Weaver; Kari A. Huppert; Tony W. Chen; Chonlarat Wichaidit; Christopher S. Cselenyi; Emilios Tahinci; Kelly Christian Meyers; Emily Waskow; Darren Orton; Adrian Salic; Laura A. Lee; David J. Robbins; Stacey S. Huppert; Ethan Lee

Misregulation of the Wnt pathway has been shown to be responsible for a variety of human diseases, most notably cancers. Screens for inhibitors of this pathway have been performed almost exclusively using cultured mammalian cells or with purified proteins. We have previously developed a biochemical assay using Xenopus egg extracts to recapitulate key cytoplasmic events in the Wnt pathway. Using this biochemical system, we show that a recombinant form of the Wnt coreceptor, LRP6, regulates the stability of two key components of the Wnt pathway (β-catenin and Axin) in opposing fashion. We have now fused β-catenin and Axin to firefly and Renilla luciferase, respectively, and demonstrate that the fusion proteins behave similarly as their wild-type counterparts. Using this dual luciferase readout, we adapted the Xenopus extracts system for high-throughput screening. Results from these screens demonstrate signal distribution curves that reflect the complexity of the library screened. Of several compounds identified as cytoplasmic modulators of the Wnt pathway, one was further validated as a bona fide inhibitor of the Wnt pathway in cultured mammalian cells and Xenopus embryos. We show that other embryonic pathways may be amendable to screening for inhibitors/modulators in Xenopus egg extracts.


Archive | 2013

Discovery and Characterization of a Selective Activator of the G-Protein Activated Inward-Rectifying Potassium (GIRK) Channel

Emily Days; Kristian Kaufmann; Ian M. Romaine; Colleen M. Niswender; Michelle Lewis; Thomas J. Utley; Yu Du; Gregory Sliwoski; Ryan D. Morrison; Eric S. Dawson; Julie L. Engers; Jerod S. Denton; J. Scott Daniels; Gary A. Sulikowski; Craig W. Lindsley; C. David Weaver


Archive | 2010

Discovery of a Highly Selective KCC2 Antagonist

Craig W. Lindsley; Michelle Lewis; Dave Weaver; Eric Delpire


Archive | 2010

Discovery of a Highly Selective in vitro and in vivo M1 Allosteric Agonist Probe

Craig W. Lindsley; Michelle Lewis; Dave Weaver


The FASEB Journal | 2009

A Small Molecule Screen Identifies Novel Inhibitors of the Neuronal K-Cl cotransporter KCC2

Eric Delpire; Emily Days; Dehui Mi; Michelle Lewis; Craig W. Lindsley; David R. Weaver


Archive | 2013

Figure 2, Compound Preparation of Probe ML297

Emily Days; Kristian Kaufmann; Ian M. Romaine; Colleen M. Niswender; Michelle Lewis; Thomas J. Utley; Yu Du; Gregory Sliwoski; Ryan D. Morrison; Eric S. Dawson; Julie L. Engers; Jerod S. Denton; J. Scott Daniels; Gary A. Sulikowski; Craig W. Lindsley; C. David Weaver


Archive | 2013

Table 1, Stability of ML297

Emily Days; Kristian Kaufmann; Ian M. Romaine; Colleen M. Niswender; Michelle Lewis; Thomas J. Utley; Yu Du; Gregory Sliwoski; Ryan D. Morrison; Eric S. Dawson; Julie L. Engers; Jerod S. Denton; J. Scott Daniels; Gary A. Sulikowski; Craig W. Lindsley; C. David Weaver


Archive | 2013

Figure 3, Shown are fits to data obtained by performing thallium flux and voltage-clamp assays on Probe ML297 at varying concentrations with cells expressing GIRK1/GIRK2

Emily Days; Kristian Kaufmann; Ian M. Romaine; Colleen M. Niswender; Michelle Lewis; Thomas J. Utley; Yu Du; Gregory Sliwoski; Ryan D. Morrison; Eric S. Dawson; Julie L. Engers; Jerod S. Denton; J. Scott Daniels; Gary A. Sulikowski; Craig W. Lindsley; C. David Weaver


Archive | 2010

Supporting Table 1, Inhibition of KCC2 (IC50) and NKCC1 (% at 5 and 50 μM) with various hit compounds

Craig W. Lindsley; Michelle Lewis; Dave Weaver; Eric Delpire


Archive | 2010

Figure 1, Known KCC2 Antagonists - Unselective and Weak (micromolar to millimolar IC50s)

Craig W. Lindsley; Michelle Lewis; Dave Weaver; Eric Delpire

Collaboration


Dive into the Michelle Lewis's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Gary A. Sulikowski

Vanderbilt University Medical Center

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

J. Scott Daniels

Vanderbilt University Medical Center

View shared research outputs
Researchain Logo
Decentralizing Knowledge